Search

Displaying results 1971 - 1980 of 2674 in total
  1. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.

  2. Drug

    Sugammadex

    go.drugbank.com/drugs/DB06206
    ApprovedInvestigational

    Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.

  3. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    [A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy.

    Products: Nra-betahistine
  4. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]

    Categories: Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
  5. Drug

    Glucosamine

    go.drugbank.com/drugs/DB01296
    Approved

    [A231894,A232289] It is currently not approved as a prescription product by the FDA, but is widely available over the counter.

  6. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    [A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products.

  7. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    [A264439] In September 2024, the FDA approved levacetylleucine for the treatment of select patients with NPC.[L51444]

  8. Drug

    Lotilaner

    go.drugbank.com/drugs/DB17992
    ApprovedInvestigationalVet approved

    [A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551]

  9. Target

    P2Y purinoceptor 2

    go.drugbank.com/bio_entities/BE0002401
    TargetHumans

    Receptor for ATP and UTP coupled to G proteins that activate a phosphatidylinositol-calcium second messenger system. The affinity range is UTP = ATP > ATP-gamma-S >> 2-methylthio-ATP = ADP

    Synonyms: ATP receptor, P2U receptor 1Function: A1 adenosine receptor binding
  10. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794] … Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992.

    Categories: Serotonin Receptor Agonists, Adrenergic alpha-2 Receptor Agonists